Bioventus (NASDAQ:BVS) Receives “Outperform” Rating from Barrington Research

Posted by Francis Steltz on Jun 30th, 2026

Bioventus (NASDAQ:BVS – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at Barrington Research in a report released on Tuesday,Benzinga reports. They presently have a $14.00 price objective on the stock. Barrington Research’s price objective points to a potential upside of 43.15% from the stock’s previous close.

BVS has been the subject of several other reports. Craig Hallum boosted their price objective on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 6th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 target price on shares of Bioventus in a research report on Tuesday, June 16th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd. CJS Securities began coverage on shares of Bioventus in a research note on Friday, March 27th. They set a “market outperform” rating and a $14.00 target price for the company. Finally, Cantor Fitzgerald raised Bioventus to a “strong-buy” rating in a report on Wednesday, March 4th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $14.20.

View Our Latest Stock Analysis on BVS

Bioventus Price Performance

Shares of NASDAQ:BVS opened at $9.78 on Tuesday. Bioventus has a fifty-two week low of $5.81 and a fifty-two week high of $11.25. The business has a 50-day simple moving average of $9.53 and a two-hundred day simple moving average of $8.76. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69. The firm has a market cap of $817.02 million, a price-to-earnings ratio of 23.85, a price-to-earnings-growth ratio of 1.26 and a beta of 0.67.

Bioventus (NASDAQ:BVS – Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.06. The business had revenue of $132.09 million for the quarter. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, analysts expect that Bioventus will post 0.77 earnings per share for the current year.

Hedge Funds Weigh In On Bioventus

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd grew its holdings in Bioventus by 17,156.2% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after purchasing an additional 5,490 shares during the period. Prelude Capital Management LLC purchased a new stake in Bioventus in the third quarter worth about $74,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Bioventus in the third quarter worth about $78,000. SG Americas Securities LLC bought a new position in shares of Bioventus in the fourth quarter worth about $80,000. Finally, Brooklyn Investment Group purchased a new position in shares of Bioventus during the 4th quarter valued at about $91,000. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Bioventus Company Profile

(Get Free Report)

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.